retatrutide clinical trial retatrutide weight loss produces up to 30.3% in Phase 3 Retatrutide dose: the complete guide

Semaglutide (Ozempic), which the patient had been taking, was discontinued, and symptoms resolved post discharge without semaglutide use for several months

Peak results, including significant weight loss, are typically observed between four and six months, with the most dramatic changes happening during the early months

Retatrutide is a next-generation triple agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously, making it the most advanced

People who switched to the experimental daily GLP-1 pill orforglipron were able to maintain their weight loss after stopping GLP-1 injections, a new trial shows.

p=0.002)

Joshua Silva, MD explains the science, the risks, and when to stop medication before pregnancy.